Page last updated: 2024-08-25

7-hydroxystaurosporine and Melanoma

7-hydroxystaurosporine has been researched along with Melanoma in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cabezas-Herrera, J; Fernández-Pérez, MP; Montenegro, MF; Piñero-Madrona, A; Rodríguez-López, JN; Sáez-Ayala, M; Sánchez-del-Campo, L	1
Agarwala, SS; Christensen, SD; Frankel, PH; Gandara, DR; Lara, PN; Li, T; Luu, T; Mack, PC; Margolin, KA	1
Arbuck, SG; Bauer, KS; Figg, WD; Fuse, E; Headlee, D; Jaken, S; Jing , X; Kuwabara, T; Lahusen, T; Lush, RM; Messmann, R; Murgo, A; Roberge, M; Sausville, EA; Senderowicz, AM	1

Trials

2 trial(s) available for 7-hydroxystaurosporine and Melanoma

Article	Year
A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial. Investigational new drugs, 2012, Volume: 30, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; California; Cell Cycle; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Protein Kinase C; Protein Kinase Inhibitors; Skin Neoplasms; Staurosporine; Time Factors; Treatment Outcome	2012
Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8 Topics: Adult; Aged; Alkaloids; Antineoplastic Agents; DNA Damage; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Hyperglycemia; Hypotension; Infusions, Intravenous; Lymphoma, Large B-Cell, Diffuse; Male; Melanoma; Middle Aged; Nausea; Neoplasms; Skin Neoplasms; Staurosporine; Vomiting	2001

Article

Year

A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial.

Investigational new drugs, 2012, Volume: 30, Issue:2

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; California; Cell Cycle; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Protein Kinase C; Protein Kinase Inhibitors; Skin Neoplasms; Staurosporine; Time Factors; Treatment Outcome

2012

Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

Topics: Adult; Aged; Alkaloids; Antineoplastic Agents; DNA Damage; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Hyperglycemia; Hypotension; Infusions, Intravenous; Lymphoma, Large B-Cell, Diffuse; Male; Melanoma; Middle Aged; Nausea; Neoplasms; Skin Neoplasms; Staurosporine; Vomiting

2001

Other Studies

1 other study(ies) available for 7-hydroxystaurosporine and Melanoma

Article	Year
Suppression of antifolate resistance by targeting the myosin Va trafficking pathway in melanoma. Neoplasia (New York, N.Y.), 2013, Volume: 15, Issue:7 Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; E2F1 Transcription Factor; Enzyme Activation; Female; Gene Silencing; Humans; Melanoma; Methotrexate; Methylation; Mice; Myosin Heavy Chains; Myosin Type V; Phosphoprotein Phosphatases; Phosphorylation; Protein Phosphatase 2C; Protein Transport; Proto-Oncogene Proteins c-akt; Signal Transduction; Staurosporine; Xenograft Model Antitumor Assays	2013

Article

Year

Suppression of antifolate resistance by targeting the myosin Va trafficking pathway in melanoma.

Neoplasia (New York, N.Y.), 2013, Volume: 15, Issue:7

Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; E2F1 Transcription Factor; Enzyme Activation; Female; Gene Silencing; Humans; Melanoma; Methotrexate; Methylation; Mice; Myosin Heavy Chains; Myosin Type V; Phosphoprotein Phosphatases; Phosphorylation; Protein Phosphatase 2C; Protein Transport; Proto-Oncogene Proteins c-akt; Signal Transduction; Staurosporine; Xenograft Model Antitumor Assays

2013